Cross-sectional study of innate and acquired immunity in gut-associated lymphoid tissue (GALT) in patients who have recovered from COVID-19
Not Applicable
Recruiting
- Conditions
- Post Covid 19 stateU09.9Post COVID-19 condition, unspecified
- Registration Number
- DRKS00027443
- Lead Sponsor
- Klinik I für Innere MedizinUniversitätsklinikum Köln (AöR)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 65
Inclusion Criteria
confirmed infection with SARS-CoV-2 three months before colonoscopy
- Age at least 18 years
- Presence of a consent form
- Stable clinical health condition
Exclusion Criteria
- No existence of a declaration of consent
- Age under 18 years
-Presence of a chronic intestinal disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Investigation of SARS-CoV- 2 persistence in GALT;<br>evaluation of innate and adaptive immunity in GALT of patients with PCS.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms in GALT are being investigated in DRKS00027443 for post-COVID-19 immunity?
How does GALT immune cell composition in post-COVID-19 patients differ from those with chronic respiratory conditions?
Which specific immune biomarkers in GALT correlate with long-term recovery outcomes in post-COVID-19 patients?
What are the potential adverse effects of GALT biopsy procedures in post-COVID-19 recovery studies?
Are there existing immunomodulatory therapies targeting GALT dysfunction in post-COVID-19 conditions?